Unibest

Pharmaceutical intermediates

Dabrafenib Mesylate Intermediates

5 pharmaceutical intermediates for Dabrafenib Mesylate. Indication: Colorectal Cancer; Glioma; Anaplastic Thyroid Cancer; Solid Tumor; Non-Small Cell Lung Cancer; Melanoma; Thyroid Tumor.

提交项目All intermediates

About Dabrafenib Mesylate

Originator
GlaxoSmithKline (GSK)
Indication
Colorectal Cancer; Glioma; Anaplastic Thyroid Cancer; Solid Tumor; Non-Small Cell Lung Cancer; Melanoma; Thyroid Tumor
Approved Date
05/29/2013
DS/DP
06/10/2025

Available intermediates

5 intermediates currently listed for Dabrafenib Mesylate. Request specifications, documentation or a quotation for any item below.

Dabrafenib Mesylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,6-Difluorobenzenesulfonyl chloride60230-36-6//
Methyl 3-amino-2-fluorobenzoate1195768-18-3//
Methyl 3-(2,6-difluorophenylsulfonaMido) -2-fluorobenzoate1195768-19-4//
2-chloro-4-methylpyrimidine13036-57-2//
2,2,2-Trimethylthioacetamide630-22-8//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDacomitinibDanicopanDapagliflozinDaridorexant HydrochlorideDarolutamideDasatinib Hydrate

Building toward Dabrafenib Mesylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →